Solstice Oncology emerged from stealth with a $225 million Series A to advance porustobart, a second-generation Fc-enhanced CTLA-4 antibody, into a Phase II setting for microsatellite-stable (MSS) colon cancer. The company plans to pair porustobart with pembrolizumab and expects enrollment to open in the fourth quarter of 2026, with data targeted for the second half of 2027. The development builds on prior clinical signals reported in Harbour BioMed-led studies, and Solstice is positioning the program for earlier intervention strategies, including potential neoadjuvant impact where the immune system remains intact. In a separate transaction, Gan & Lee licensed GLP-1 bofanglutide to Menarini Group for exclusive registration and commercialization across the EU and multiple additional markets, including the UK and several Nordic and Balkan countries. These moves reflect continued capital formation and global commercialization pushes around immuno-oncology and metabolic drug candidates.